FIND A CLINICAL TRIAL

CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 14-Apr-20
ARO-013
A Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 03-Mar-20
(Janssen) JNJ-74494550 AML1003
An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 02-Mar-20
(ODI) ODO-TE-B202
A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer.
CLICK HERE FOR DETAILS
CANCER TYPE: Gynecology
LOCATION: Calgary
OPEN DATE: 27-Feb-20
(LHSC) ORATOR II
A Phase II Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 21-Feb-20
QBGJ098-301 PROOF
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: the PROOF Trial
CLICK HERE FOR DETAILS
CANCER TYPE: Neuroendocrine
LOCATION: Edmonton
OPEN DATE: 20-Feb-20
DX-GAL-001
A Phase I/II Study of Gallium-68 HA-DOTATATE ([68]Ga-HA-DOTATATE) in Patients with Known or Suspected Somatostatin Receptor Positive Tumours
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 07-Feb-20
CA209-73M
A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab maintenance Therapy After Nivolumab and Ipilimumab Induction (CheckMate 73M: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 73M)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 31-Jan-20
TED14856
A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, then in Combination with Palbociclib in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 31-Jan-20
(CCTG) MAC.24 / S1418 / BR006 / MK-3475-242
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 14-May-19
Pfizer B1761031
A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33-POSITIVE ACUTE MYELOID LEUKEMIA. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 30-Aug-18
CPI-0610
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis). Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Pediatrics
LOCATION: Edmonton
OPEN DATE: 02-Feb-18
AGCT1531
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
 
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 24-Nov-17
Astellas 2215-CL-0201 LaceWing
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib),Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy. Conducted at the University of Alberta.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 17-Nov-16
Stemline SL-401-0314
SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Edmonton
OPEN DATE: 23-May-16
GH29914
A PHASE IB/II MULTI-ARM STUDY WITH VENETOCLAX IN COMBINATION WITH COBIMETINIB AND VENETOCLAX IN COMBINATION WITH IDASANUTLIN IN PATIENTS AGED ≥60 YEARS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WHO ARE NOT ELIGIBLE FOR CYTOTOXIC THERAPY. Conducted at the University of Alberta Hospital.
CLICK HERE FOR DETAILS
CANCER TYPE: Head & Neck
LOCATION: Calgary
OPEN DATE: 29-Feb-16
NRG - HN001
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 02-Feb-16
NRG - BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Hematology
LOCATION: Calgary
OPEN DATE: 11-Sep-15
(Karyopharm) KCP-330-017 / STOMP
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Resistant/Refractory Multiple Myeloma
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Edmonton
OPEN DATE: 17-Aug-15
NCIC MA-32D
Change in mammographic density with metformin use: a Companion study to NCIC study MA.32
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Calgary
OPEN DATE: 30-Jul-15
(SHSC) OZM-053
A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 03-Jun-15
OCOG-2013-LUSTRE
A Randomized Trial of Medically-Inoperable Stage I Non-Small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy (LUSTRE)
CLICK HERE FOR DETAILS
CANCER TYPE: Lung
LOCATION: Calgary
OPEN DATE: 19-Mar-15
(CCTG) BR.31
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Breast
LOCATION: Calgary
OPEN DATE: 04-Dec-14
RTOG 1304
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. (NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT)
CLICK HERE FOR DETAILS
CANCER TYPE: Genitourinary
LOCATION: Edmonton
OPEN DATE: 26-Sep-12
RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 11-Oct-11
DX-CPERT-001
A Phase I Study of Cyclotron -produced Tc-99m Pertechnetate (CPERT) in Patients with Thyroid Cancer
CLICK HERE FOR DETAILS
CANCER TYPE: Radiation Therapy
LOCATION: Edmonton
OPEN DATE: 10-May-11
Seed Movement
Seed movement in permanent prostate brachytherapy implants: Clinical measurement and dosimetric consequences.
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Calgary
OPEN DATE: 15-Jul-10
(CCTG) CO.21 / CHALLENGE
A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 16-Dec-08
DX-FLT-002
A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-deoxy-3'-L-fluorothymidine (18F-FLT) in Patients with Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, or Pancreas, and with Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma (DX-FLT-002)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 30-Nov-08
CS-FAZ-005
A Pilot Study of the Role of 18F-FAZA in Combination with FluGlucoScan® Injection PET Scans in Assessing Early Functional Response in Patients with Inoperable Non-Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy. (CS-FAZ-005)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 11-Dec-07
DX-FLU-001
An Observational Pilot Study of 18F Sodium Fluoride Whole Body Scans in Patients for whom 99mTc Bone Scans Would Normally be Indicated
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 14-Nov-06
DX-FLT-001
An Imaging Pilot Study of 18F-fluoro-3’-deoxy-3’-L-fluorothymidine (18F-FLT) in Patients with Locally Advanced or Metastatic Pancreatic Cancer who will be Treated with Gemcitabine (DX-FLT-001)
CLICK HERE FOR DETAILS
CANCER TYPE: Oncologic Imaging
LOCATION: Edmonton
OPEN DATE: 01-May-06
DX-FAZ-001
A Phase I/II Imaging Study of 1-a-D-(5-deoxy-5-18F-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA) in Patients with Known Squamous Cell Carcinoma of the Head & Neck, Small Cell & Non-Small Cell Carcinoma of the Lung, Lymphoma or Glioblastoma Multiforme. (DX-FAZ-001)
CLICK HERE FOR DETAILS
CANCER TYPE: Gastrointestinal
LOCATION: Edmonton
OPEN DATE: 05-May-05
TSX
Thymidylate Synthase Polymorphisms as a predictor of toxicity to Capecitabine based adjuvant chemotherapy in colon cancer treatment
CLICK HERE FOR DETAILS